This study aims to compare NK cells obtained from multiple sclerosis (MS) patients receiving interferon-β1 and fingolimod therapies. Fingolimod reduced the CD56bright NK cell subset. The remaining CD56dim NK cells displayed NKG2D, NKp46, CD107a, and IFN-γ levels similar to those from the patients under interferon-β1 therapy. Alternatively, comparative transcriptomics and pathway analyses revealed significant distinctions between two therapy modalities. Molecular signature of the CD56dim NK cells from fingolimod-treated MS patients was closely associated to those from healthy subjects. The basic assets of NK cells were modestly influenced by interferon-β1 and fingolimod, however transcriptomics showed profound alterations in NK responses.

中文翻译：

---

干扰素-β1 和芬戈莫德治疗多发性硬化症患者 NK 细胞差异调节的免疫学和转录组学方法

本研究旨在比较从接受干扰素-β1 和芬戈莫德治疗的多发性硬化症 (MS) 患者中获得的 NK 细胞。芬戈莫德减少了 CD56bright NK 细胞亚群。剩余的 CD56dim NK 细胞显示出与接受干扰素-β1 治疗的患者相似的 NKG2D、NKp46、CD107a 和 IFN-γ 水平。或者，比较转录组学和通路分析揭示了两种治疗方式之间的显着区别。芬戈莫德治疗的 MS 患者的 CD56dim NK 细胞的分子特征与健康受试者的细胞特征密切相关。NK 细胞的基本资产受到干扰素-β1 和芬戈莫德的适度影响，但转录组学显示 NK 反应发生了深刻的变化。